Meanwhile,
Weight loss medications tested new new:
The stars against diabetes. For example, weight loss, such as the Mounjaro and the Zepbound of Eli Lilly, as well as the Ozempic and Wegovy competitors of Novo Nordisk, generated more than $ 40 billion in sales together last year and should reach $ 60 billion in 2025. Moreover, Despite this success. Consequently, Novo Nordisk said Tuesday Generics from his weight loss medicine in the United States, as well as Lilly competition on several markets, should slow down sales of Wegovy this year.
Laboratories test these GLP-1 drugs for other medical uses. Moreover, with the aim of increasing their sales and expanding their care by insurers, with some success. However, Here is an overview of other pathologies for which these treatments are used or under evaluation:
Alcohol dependence – Weight loss medications tested new new
- A study conducted by the Rigshospitalet Psychiatric Center of Copenhagen’s University examines whether semaglutide weight loss medications tested new new – active ingredient of Wegovy. Ozempic – can help reduce alcohol consumption in 108 patients with obesity and disorders related to alcohol use.
Alzheimer’s disease – Weight loss medications tested new new
- Novo Nordisk tests semaglutide in an advanced phase test in patients with an early stage of Alzheimer’s disease. The study, which plans to include 1,840 patients, could deliver its first results at the end of this year.
Cardiovascular diseases – Weight loss medications tested new new
- Eli Lilly was testing the shooting – Main ingredient of Mounjaro. Zepbound – in patients with heart failure and obesity. The company planned to include around 700 people. but announced in May to have withdrawn its request for authorization in the United States for this indication.
- The European Medicines Agency argued. in September 2024, the use of the NOVO semaglutide to alleviate the symptoms of heart failure in obese people.
Chronic kidney disease
- Ozempic de Novo is authorized in the United States to reduce the risk of kidney failure. disease progression and weight loss medications tested new new cardiac death in diabetics with chronic kidney disease.
- Lilly’s shooting is the subject of an intermediate study in patients with both obesity and chronic kidney disease. Up to 140 participants should be recruited, with expected results next year.
Liver disease
- Novo tests semaglutide in an advanced phase test in patients with non -alcoholic steatohepatitis (NASH). a common form but difficult to deal with liver disease. The study, which should include around 1,200 patients, should be completed in April 2029.
- Lilly’s shooting has enabled 74 % of patients to obtain an absence from the disease without worsening hepatic fibrosis after 52 weeks. against 13 % on placebo, in an intermediate trial for NASH (now called steato -Hepatitis associated with metabolic dysfunction, or Mash).
Neurological disorders
- Researchers from Danish Headache Center assess the semaglutide. associated with a very low calorie diet, as a treatment for idiopathic intracranial hypertension of recent appearance, a condition linked to obesity weight loss medications tested new new characterized by an elevation of pressure inside the skull. The study, which recruited around 50 patients, had to end in October 2025.
Sleep apnea
- Zepbound received in December 2024 the approval of the American Food. Drug Administration for the treatment of obstructive sleep apnea, thus becoming the first authorized drug to directly treat patients with this frequent disorder which disrupts breathing during sleep.
(Reportable with Patrick Wipprove â New York, Roy Serwer, Chishosh, Mahathy Mahathy èt
Further reading: A small aperitif? Olives, cheeses, sausages … Watch out for these “salty traps” not very good for the arteries – Duchenne myopathy: Starting the pivot phase of the genethon gene therapy test – Physical activity can improve the mental health of adolescents – It is the only bottled water without microplastics according to a study and you will no longer buy it by chance – A demustication operation in a district of Toulouse after the detection of an imported case of dengue.
